The primate model for understanding and restoring vision
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Retinal degenerative diseases caused by photoreceptor cell death are major causes of irreversible vision loss. As only primates have a macula, the nonhuman primate (NHP) models have a crucial role not only in revealing biological mechanisms underlying high-acuity vision but also in the development of therapies. Successful translation of basic research findings into clinical trials and, moreover, approval of the first therapies for blinding inherited and age-related retinal dystrophies has been reported in recent years. This article explores the value of the NHP models in understanding human vision and reviews their contribution to the development of innovative therapeutic strategies to save and restore vision.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Selective Attention Gates Visual Processing in the Extrastriate Cortex
Moran, J., & Desimone, R. (1985) · Science · doi:10.1126/science.4023713 · Cited by 2,433 · cited 1×
“The neural circuits that give rise to the perceptual and behavioral advantages conferred by attention have been studied in NHPs for decades, focused at first on single neurons in the visual cortex (36) that change their responsiveness or gain (37, 38).”
BackgroundVisual perception in a blind subject with a chronic microelectronic retinal prosthesis
Humayun, M. S., Weiland, J. D., Fujii, G. Y., Greenberg, R., Williamson, R., Little, J., Mech, B., Cimmarusti, V., Van Boemel, G., Dagnelie, G., et al. (2003) · Vision Research · doi:10.1016/s0042-6989(03)00457-7 · Cited by 856 · cited 1×
“After the clear demonstration that electrical currents can activate the retina (111), an initial prototype with 16 electrodes chronically implanted in blind patients showed that electrical stimulation can provide visual perception with maintained activity over time (112).”
BackgroundDalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., Flannery, J. G., & Schaffer, D. V. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005708 · Cited by 734
Self-citationSpatial attention decorrelates intrinsic activity fluctuations in macaque area V4
Mitchell, J. F., Sundberg, K. A., & Reynolds, J. H. (2009) · Neuron · doi:10.1016/j.neuron.2009.09.013 · Cited by 710
Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10
Maeder, M. L., Stefanidakis, M., Wilson, C. J., Baral, R., Barrera, L. A., Bounoutas, G. S., Bumcrot, D., Chao, H., Ciulla, D. M., DaSilva, J. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0327-9 · Cited by 707
Cell Types of the Human Retina and Its Organoids at Single-Cell Resolution
Cowan, C. S., Renner, M., De Gennaro, M., Gross-Scherf, B., Goldblum, D., Hou, Y., Munz, M., Rodrigues, T. M., Krol, J., Szikra, T., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.013 · Cited by 654
Self-citationAchberger, K., Probst, C., Haderspeck, J., Bolz, S., Rogal, J., Chuchuy, J., Nikolova, M., Cora, V., Antkowiak, L., Haq, W., et al. (2019) · eLife · doi:10.7554/elife.46188 · Cited by 380
Donahue, C. J., Sotiropoulos, S. N., Jbabdi, S., Hernandez-Fernandez, M., Behrens, T. E., Dyrby, T. B., Coalson, T., Kennedy, H., Knoblauch, K., Van Essen, D. C., et al. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.0493-16.2016 · Cited by 380
Five-year safety and performance results from the argus II retinal prosthesis system clinical trial.
da Cruz, L., Dorn, J. D., Humayun, M. S., Dagnelie, G., Handa, J., Barale, P.-O., Sahel, J.-A., Stanga, P. E., Hafezi, F., Safran, A. B., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.06.049 · Cited by 359 · cited 1×
“The current state of the art is represented by the Argus II implant, which received the CE (Conformité Européenne) mark and FDA approval (humanitarian exemption) for commercialization in Europe and the United States, respectively (110), and was discontinued in 2019.”
MethodSelf-citationda Cruz, L., Coley, B. F., Dorn, J., Merlini, F., Filley, E., Christopher, P., Chen, F. K., Wuyyuru, V., Sahel, J., Stanga, P., et al. (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2012-301525 · Cited by 359 · cited 1×
“The current Argus II device with a 60-electrode array allowed some patients to recognize letters and even read simple words (113).”
MethodSelf-citationEffects of Spatial Attention on Contrast Response Functions in Macaque Area V4
Williford, T., & Maunsell, J. H. R. (2006) · Journal of Neurophysiology · doi:10.1152/jn.01207.2005 · Cited by 353
Heier, J. S., Kherani, S., Desai, S., Dugel, P., Kaushal, S., Cheng, S. H., Delacono, C., Purvis, A., Richards, S., Le-Halpere, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30979-0 · Cited by 229 · cited 8×
“NHPs have also been used for modeling and developing treatments for complex diseases such as diabetic retinopathy, choroidal neovascularization, wet AMD (47, 48), and glaucoma (49, 50).”
BackgroundInfluentialA comparison of some organizational characteristics of the mouse central retina and the human macula
Volland, S., Esteve-Rudd, J., Hoo, J., Yee, C., & Williams, D. S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125631 · Cited by 229 · cited 1×
“Moreover, photoreceptor cell organization within the macula is similar in humans and NHPs (27), with densely packed cones in the fovea of up to 160,000 to 200,000 cones/mm(2); cone photoreceptor packing density decreases faster with increasing eccentricity from Fig.”
BackgroundEmerging therapies for inherited retinal degeneration
Scholl, H. P. N., Strauss, R. W., Singh, M. S., Dalkara, D., Roska, B., Picaud, S., & Sahel, J.-A. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2838 · Cited by 219 · cited 1×
“For these blinding conditions, retinal implants and gene and cell therapy may allow therapeutic intervention at various stages of the disease (3, 4).”
BackgroundSelf-citationJüttner, J., Szabo, A., Gross-Scherf, B., Morikawa, R. K., Rompani, S. B., Hantz, P., Szikra, T., Esposti, F., Cowan, C. S., Bharioke, A., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0431-2 · Cited by 218
Self-citationIntravitreal injection of AAV2 transduces macaque inner retina
Yin, L., Greenberg, K., Hunter, J. J., Dalkara, D., Kolstad, K. D., Masella, B. D., Wolfe, R., Visel, M., Stone, D., Libby, R. T., et al. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6250 · Cited by 212 · cited 1×
“Although a healthy NHP is an excellent model to determine the adequacy of AAV capsids and doses in combination with appropriate injection routes (96, 101, 104, 105), studies in mouse models, human iPSC-derived organoids (20, 106), and postmortem human retinal explants (70, 71, 95) are required to complement findings i…”
BackgroundSelf-citationStingl, K., Schippert, R., Bartz-Schmidt, K. U., Besch, D., Cottriall, C. L., Edwards, T. L., Gekeler, F., Greppmaier, U., Kiel, K., Koitschev, A., et al. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00445 · Cited by 198 · cited 1×
“Another photovoltaic subretinal implant with a wire connection to a battery located behind the ear has obtained the CE mark following positive results in blind patients (117).”
BackgroundRakoczy, E. P., Lai, C.-M., Magno, A. L., Wikstrom, M. E., French, M. A., Pierce, C. M., Schwartz, S. D., Blumenkranz, M. S., Chalberg, T. W., Degli-Esposti, M. A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00345-1 · Cited by 189 · cited 8×
“NHPs have also been used for modeling and developing treatments for complex diseases such as diabetic retinopathy, choroidal neovascularization, wet AMD (47, 48), and glaucoma (49, 50).”
BackgroundInfluentialKotterman, M. A., Yin, L., Strazzeri, J. M., Flannery, J. G., Merigan, W. H., & Schaffer, D. V. (2015) · Gene Therapy · doi:10.1038/gt.2014.115 · Cited by 169 · cited 1×
“Although a healthy NHP is an excellent model to determine the adequacy of AAV capsids and doses in combination with appropriate injection routes (96, 101, 104, 105), studies in mouse models, human iPSC-derived organoids (20, 106), and postmortem human retinal explants (70, 71, 95) are required to complement findings i…”
BackgroundTargeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors
Kay, C. N., Ryals, R. C., Aslanidi, G. V., Min, S. H., Ruan, Q., Sun, J., Dyka, F. M., Kasuga, D., Ayala, A. E., Van Vliet, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062097 · Cited by 168
Preclinical safety evaluation of AAV2-sFLT01— a gene therapy for age-related macular degeneration
MacLachlan, T. K., Lukason, M., Collins, M., Munger, R., Isenberger, E., Rogers, C., Malatos, S., DuFresne, E., Morris, J., Calcedo, R., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.258 · Cited by 166
Roska, B., & Sahel, J.-A. (2018) · Nature · doi:10.1038/s41586-018-0076-4 · Cited by 161
Self-citationNoninvasive gene delivery to foveal cones for vision restoration
Khabou, H., Garita-Hernandez, M., Chaffiol, A., Reichman, S., Jaillard, C., Brazhnikova, E., Bertin, S., Forster, V., Desrosiers, M., Winckler, C., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.96029 · Cited by 124 · cited 6×
“Although a healthy NHP is an excellent model to determine the adequacy of AAV capsids and doses in combination with appropriate injection routes (96, 101, 104, 105), studies in mouse models, human iPSC-derived organoids (20, 106), and postmortem human retinal explants (70, 71, 95) are required to complement findings i…”
BackgroundMethodInfluentialSelf-citationAAV9 targets cone photoreceptors in the nonhuman primate retina
Vandenberghe, L. H., Bell, P., Maguire, A. M., Xiao, R., Hopkins, T. B., Grant, R., Bennett, J., & Wilson, J. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053463 · Cited by 97 · cited 2×
“Based on these studies, AAV9 and its variants have been shown to lead to efficient foveal cone transduction when injected into the subretinal space (20, 98).”
BackgroundMethodOptogenetic Light Sensors in Human Retinal Organoids
Garita-Hernandez, M., Guibbal, L., Toualbi, L., Routet, F., Chaffiol, A., Winckler, C., Harinquet, M., Robert, C., Fouquet, S., Bellow, S., et al. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00789 · Cited by 65 · cited 1×
“Although a healthy NHP is an excellent model to determine the adequacy of AAV capsids and doses in combination with appropriate injection routes (96, 101, 104, 105), studies in mouse models, human iPSC-derived organoids (20, 106), and postmortem human retinal explants (70, 71, 95) are required to complement findings i…”
BackgroundSelf-citationChanges in adeno-associated virus-mediated gene delivery in retinal degeneration
Kolstad, K. D., Dalkara, D., Guerin, K., Visel, M., Hoffmann, N., Schaffer, D. V., & Flannery, J. G. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.194 · Cited by 63
Self-citationAAV‐mediated gene delivery in Dp71‐null mouse model with compromised barriers
Vacca, O., Darche, M., Schaffer, D. V., Flannery, J. G., Sahel, J., Rendon, A., & Dalkara, D. (2014) · Glia · doi:10.1002/glia.22617 · Cited by 48
Self-citation
Cited by
Partial recovery of visual function in a blind patient after optogenetic therapy
Sahel, J.-A., Boulanger-Scemama, E., Pagot, C., Arleo, A., Galluppi, F., Martel, J. N., Esposti, S. D., Delaux, A., de Saint Aubert, J.-B., de Montleau, C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01351-4 · Cited by 700
Self-citationCell Atlas of The Human Fovea and Peripheral Retina
Yan, W., Peng, Y.-R., van Zyl, T., Regev, A., Shekhar, K., Juric, D., & Sanes, J. R. (2020) · Scientific Reports · doi:10.1038/s41598-020-66092-9 · Cited by 283
Gelfman, C. M., Grishanin, R., Bender, K. O., Nguyen, A., Greengard, J., Sharma, P., Nieves, J., Kiss, S., & Gasmi, M. (2021) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2021.0001 · Cited by 55
“Another important advantage of NHPs for the development of ocular therapeutics is the applicability of noninvasive methods and instrumentation of ocular imaging and electrophysiology used in humans.(12) The NHP studies reviewed in this study evaluated the pharmacokinetics, pharmacology, and safety of a single IVT inje…”
MethodSarrazin, N., Chavret-Reculon, E., Bachelin, C., Felfli, M., Arab, R., Gilardeau, S., Brazhnikova, E., Dubus, E., Yahia Cherif, L., Lorenceau, J., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2115973119 · Cited by 15
“aInstitut du Cerveau, Sorbonne Universit e, INSERM, CNRS, F-75013 Paris, France; bInstitut de la Vision, Sorbonne Universit e, INSERM, CNRS, F-75012 Paris, France; cIntegrative Neuroscience and Cognition Center, Universit e de Paris, CNRS, F-75006 Paris, France; dClinique V et erinaire Voltaire, F-92600 Asni eres-sur-…”
BackgroundSelf-citation
Metadata
- Authors
- Picaud, S., Dalkara, D., Marazova, K., Goureau, O., Roska, B., & Sahel, J.-A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2019-12-23
- Volume
- 116
- Issue
- 52
- Pages
- 26280-26287
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2997216769
- Cited by
- 113
- References
- 27
- FWCI
- 2.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.